Lacosamid Puren

Lacosamide, the active ingredient in Lacosamid Puren, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures and epilepsy in patients who require additional seizure control as part of a comprehensive management plan.

GNH USA supplies Lacosamid Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet the needs of healthcare providers.

Lacosamide is an antiepileptic drug used to manage focal seizure disorders and related epilepsy syndromes.

Partial‑onset seizures: reduces seizure frequency in patients with focal seizures. Focal epilepsy: provides adjunctive therapy for patients whose seizures are not controlled by other agents. Refractory epilepsy: used as an add‑on medication when monotherapy fails to achieve adequate control.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache - Diplopia (double vision) - Blurred vision

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Blood dyscrasias (e.g., agranulocytosis) - Cardiac arrhythmias (e.g., PR‑interval prolongation) - Anaphylactic reactions - Hepatic injury

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: adjust dose and monitor renal function. - Hepatic impairment: use caution and assess liver enzymes regularly. - Pregnancy Category B: discuss potential risks with the prescriber. - Driving and operating machinery: advise patients about possible dizziness. - Concomitant antiepileptic drugs: monitor for additive CNS effects. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines; clinical judgment is required.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) may reduce lacosamide exposure. - Co‑administration with other sodium‑channel blockers may increase risk of CNS depression. - Alcohol: may potentiate dizziness and sedation.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine) can modestly increase lacosamide levels. - Anticoagulants (e.g., warfarin) may require INR monitoring. - Hormonal contraceptives: efficacy may be reduced; advise alternative contraception.